share_log

石四药集团(02005)第一季度股东应占溢利约4.16亿港元 同比增长约14.6%

Profit attributable to shareholders of Shisi Pharmaceutical Group (02005) in the first quarter was approximately HK$416 million, up about 14.6% year over year

Zhitong Finance ·  Apr 16 16:35

According to the Zhitong Finance App, Shijiyao Group (02005) announced that the group's sales are mainly carried out in China and are denominated in RMB. In the 3 months ending March 31, 2024, the RMB depreciated by about 3.6% against the Hong Kong dollar compared to the same period in 2023. As a result, in Hong Kong dollars, the Group's unaudited turnover for the three months ended March 31, 2024 increased by only 2.9% over the same period in 2023 to approximately HK$1,799 billion (same period in 2023: approximately HK$1,749 million).

The Group's unaudited gross profit for the three months ended 31 March 2024 increased by 2.3% to approximately HK$1,031 million (same period in 2023: approximately HK$1,008 million). The Group's unaudited gross margin for the three months ended March 31, 2024 was approximately 57.3%, a slight decrease of 0.3 percentage points from the same period in 2023. For the three months ended 31 March 2024, profit attributable to shareholders of the Group's unaudited companies increased by about 14.6% over the same period in 2023 to approximately HK$416 million (same period in 2023: approximately HK$363 million).

For the three months ended 31 March 2024, the Group's unaudited turnover of approximately HK$1,799 billion comprised the following:

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment